Viatris (VTRS) Stock Price, News & Analysis

Company Overview

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that develops, manufactures and commercializes medicines. Its portfolio includes generic and branded medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. The company serves a broad range of therapeutic areas, including cardiovascular disease, infectious diseases, central nervous system disorders, immunology, oncology and women’s health.

Viatris was formed in 2020 through the combination of Mylan N.V. and Upjohn, Pfizer’s off-patent branded and generic medicines business. The company’s portfolio includes established products such as Lipitor, Lyrica, Viagra and Celebrex, alongside Mylan’s generic medicines and biosimilars. Viatris also provides medicines through a combination of internal development, manufacturing and commercialization capabilities and partnerships with other pharmaceutical companies.

Based in Pittsburgh, Pennsylvania, Viatris operates internationally and makes its products available in more than 165 countries and territories. The company is led by Chief Executive Officer Scott A. Smith, who joined Viatris’ leadership team after holding senior roles in the healthcare and pharmaceutical industries.

Key Stats

• Today's Range: $17.54 to $17.75
• 50-Day Range: $16.04 to $17.86
• 52-Week Range: $9.47 to $18.39
• Volume: 263,972 shs
• Average Volume: 10.11 million shs
• Market Capitalization: $20.38 billion
• P/E Ratio: N/A
• Dividend Yield: 2.71%
• Price Target: $19.50
• Consensus Rating: Moderate Buy

Viatris Stock Analysis - MarketRank™

Viatris scored higher than 46% of companies evaluated by MarketBeat, and ranked 591st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Viatris has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Viatris is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Viatris has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.75%

Earnings Growth

Earnings for Viatris are expected to grow by 6.75% in the coming year, from $2.52 to $2.69 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viatris is -49.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viatris is -49.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Viatris has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Viatris has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.56% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 5.57.

Change versus previous month

Short interest in Viatris has recently increased by 5.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Viatris pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Viatris does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Viatris will have a dividend payout ratio of 17.84% next year. This indicates that Viatris will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.53

News Sentiment

Viatris has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Viatris this week, compared to 5 articles on an average week.

Search Interest

15 people have searched for VTRS on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Viatris to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Viatris insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.28% of the stock of Viatris is held by insiders.

Percentage Held by Institutions

79.88% of the stock of Viatris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Record date for 9/16 Dividend: 8/21/2026
• Ex-Dividend for 9/16 Dividend: 8/21/2026
• Dividend Payable: 9/16/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VTRS
• CIK: 1792044
• Web: www.viatris.com
• Phone: (724) 514-1800
• Fax: 724-514-1870
• Employees: 30,000
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Viatris: $19.50
• High Price Target: $25.00
• Low Price Target: $13.00
• Potential Upside/Downside: +9.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.06
• P/E Growth: 1.95
• Net Income: -$3.51 billion
• Net Margins: -2.79%
• Pretax Margin: -4.49%
• Return on Equity: 20.02%
• Return on Assets: 8.02%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 1.58
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $14.30 billion
• Price / Sales: 1.43
• Cash Flow: $7.38 per share
• Price / Cash Flow: 2.41
• Book Value: $12.77 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 1,148,590,000
• Free Float: 1,145,375,000
• Market Cap: $20.42 billion
• Optionable: Optionable
• Beta: 0.89